2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.30 Landscape of EGFR Mutations and Real-World Experience of Therapeutic Interventions

EP.12A.30 Landscape of EGFR Mutations and Real-World Experience of Therapeutic Interventions - A Community Oncology Study

Back to course

Pdf Summary

This study explores the landscape of EGFR mutations in patients with non-small cell lung carcinoma (NSCLC) in community oncology settings, focusing on those diagnosed with EGFR mutations between March 2018 and December 2023. The research involved 1068 NSCLC patients, predominantly suffering from adenocarcinoma (81.55%). Among them, 35.7% were identified with EGFR mutations, with a median age of 64 and a near-equal gender distribution.<br /><br />EGFR testing was conducted using various methods: liquid biopsy-based NGS (10%), PCR (52%), and tissue-based NGS (38%). The study highlights that 84.88% of the patients were at stage IV when diagnosed. Most of the patients (75.7%) received tyrosine kinase inhibitors (TKIs) like Gefitinib, Erlotinib, Afatinib, and Osimertinib as first-line treatments, with varying usage rates. Notably, 32% of those received TKI combined with chemotherapy, yielding a median survival of 35 months.<br /><br />The research underscores the importance of Next-Generation Sequencing (NGS) in identifying mutations that can tailor personalized treatment strategies, potentially enhancing patient outcomes. This study's real-world data reflect and align with existing literature, affirming the critical role of genomic profiling for better management of NSCLC in clinical settings. <br /><br />The study highlights a scarcity of real-world data on EGFR and related co-mutations, especially in Western India, aiming to fill this gap. By documenting the spectrum of mutations, patient profiles, treatment patterns, and survival outcomes, the study emphasizes the importance of personalized medicine in adapting treatment strategies for metastatic lung cancer. Overall, the findings validate the significance of EGFR as a primary target in lung cancer treatment, expanding therapeutic options and improving patient care in community oncology practices.

Asset Subtitle

Kshitij Joshi

Meta Tag

Speaker Kshitij Joshi

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR mutations

NSCLC

community oncology

adenocarcinoma

tyrosine kinase inhibitors

Next-Generation Sequencing

personalized medicine

genomic profiling

metastatic lung cancer

Western India